Horizon Discovery (United Kingdom) a commercial-stage translational genomics company focused on drug discovery and molecular diagnostics, closed a $18.6M Series C financing. Participants include MVM Life Sciences, DFJ Esprit and Roche Venture Fund.
Thanx for your patience as we catch-up.

LifeBond (Israel) a clinical-stage medical device company focused on surgical hemostats, sealants and coagulation, closed a $20M Series C financing. Participants include Giza Venture Capital, Aurum Ventures, Johnson & Johnson Development Corp. and Pitango Venture Capital.
Thanx for your patience as we catch-up.

Enobia Pharma (Canada) a clinical-stage biotech company focused on hypophosphatasia, closed a $40M Series D financing. Participants include OrbiMed, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.
Thanx for your patience as we catch-up.

Spinifex Pharmaceuticalsx (Australia) a clinical-stage biotechnology company focused on neuropathic pain, closed a $6.4M Series B financing. Participants include GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest.
Thanx for your patience as we catch-up.

Zymeworks (Canada) a preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease, closed a $8.1M Series D financing. Participants include CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund.
Thanx for your patience as we catch-up.

SpineGuard (France) a commercial-stage medical device company focused on increasing accuracy and efficiency of pedicle screw placement in spine surgery, closed a $6.2M Series B bringing the total financing to $15M. Participants include Credit Agricole Private Equity, Innoven Partenaires, A Plus Finance and Delta Partners.
Thanx for ur patience as we catch-up.

MSI Methylation Sciences (Canada) a preclinical-stage pharmaceutical company focused on depression, closed a $18.2M Series A financing. Participants include Inventages, GrowthWorks and BC Advantage Funds.

Miracor Medical Systems (Austria) a development-stage medical device company focused on acute coronary syndrome and heart failure, closed a $10M Series B financing. Participants include Austria Wirtschaftsservice, SHS, Earlybird and Delta Partners.

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.

Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

Enerkem (Canada) a development-stage waste-to-biofuels and chemicals company, closes a $60M Series C financing. Participants include Valero Energy, Waste Management, Rho Ventures, Braemar Energy Ventures and Cycle Capital.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact [...]

Avantium (Netherlands) a commercial-stage clinical research organization focused on high-throughput R&D, closed a $36.2M Series B financing. Participants include Sofinnova Partners, Aster Capital, De Hoge Dennen, Aescap Venture, Capricorn Cleantech Fund, ING Corporate Investments and Navitas Capital.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]